Harriet Latham Robinson

Chief Scientific Officer-Emeritus, GeoVax Labs, Inc.

Harriet Latham Robinson founded GeoVax Labs, Inc. and GeoVax, Inc. Presently, she holds the position of Chief Scientific Officer-Emeritus at GeoVax Labs, Inc.

Dr. Robinson previously was Professor at University of Massachusetts Medical Center, Member of American Society for Microbiology, Member of National Institutes of Health, Member of World Health Organization, Member of Bill & Melinda Gates Foundation Trust, Professor at Emory University, Member of The Rockefeller Foundation, Member of National Foundation for Infectious Diseases and Member of American Academy of Sciences.

She received an undergraduate degree from Swarthmore College and a graduate degree and a doctorate from Massachusetts Institute of Technology.

https://www.wsj.com/market-data/quotes/GOVXW/company-people/executive-profile/15427890

Harriet L Robinson

https://www.ancestry.com/discoveryui-content/view/320924974:62209?tid=&pid=&queryId=f93195acbecf888461229a76971fea38&_phsrc=llt1487&_phstart=successSource

in the U.S., Index to Public Records, 1994-2019

DetailSource

• Name : Harriet L Robinson / [H L Robinson]

• Birth Date : Feb 1938

• Residence Date : 2010-2020

• Address : 620 Sand Hill Rd Apt 124d / Palo Alto, California, USA / 94304

• Second Residence Date : 2016

• Second Address : 1642 Mason Mill Rd Ne / Atlanta, Georgia, USA / 30329

• Third Residence Date : 1983-1999

• Third Address : 3 Birchwood Dr / Southborough, Massachusetts, USA / 01772

• Fourth Residence Date : 1990-1997

• Fourth Address : 30 Birchwood Dr Southborough, Massachusetts, USA / 01772

Born Feb 10, 1938

https://vaccines.emory.edu/faculty-evc/affiliate/robinson_harriet.html

2021-12-16-emory-edu-vaccines-faculty-robinson-harriet.pdf

2021-12-16-emory-edu-vaccines-faculty-robinson-harriet-img-1.jpg

Harriet Robinson, PhD

Affiliate Faculty

Emory Vaccine Center

Chief Scientific Officer

GeoVax, Inc

Emeritus Professor of Microbiology and Immunology

Emory University School of Medicine

Phone: 678-384-7223

Fax: 678-384-7281

Email: Email: hrobinson@geovax.com

Biography

Dr. Robinson has a multi-protein clade B DNA/MVA vaccine regimen in clinical trials through the US HIV vaccine Trials Network (HVTN). The vaccine was developed in Dr. Robinson's former laboratory at the Emory Vaccine Center in collaboration with Dr. Bernard Moss's laboratory at the US NIH.

LinkedIN (Dec 16, 2021) - "Harriet L. Robinson : Director HIV Vaccines at GeoVax Labs, Inc."

https://www.linkedin.com/in/harriet-l-robinson-b3b745a

2021-12-16-linkedin-com-harriet-l-robinson-b3b745a.pdf

https://drive.google.com/file/d/1W5yw5TCBpIF6N_sc1GtaAyAvm9jpkGse/view?usp=sharing

2021-12-16-linkedin-com-harriet-l-robinson-b3b745a-img-1.jpg

https://drive.google.com/file/d/1HjliJajzzNmAPjLc5L8qKipE3hKrdFSH/view?usp=sharing

Atlanta, Georgia, United States500+ connections

GeoVax Labs, Inc.

Massachusetts Institute of Technology

Company Website

About

Harriet L. Robinson leads the HIV vaccine program at GeoVax, Inc., a biotech company she co-founded to facilitate taking the vaccine from the research laboratory to clinical use. The HIV vaccine uses a single DNA prime and modified vaccinia Ankara (MVA) boost to express virus-like particles displaying trimeric, fusion-competent Env. The vaccine addresses the clade B epidemic in the Americas, Europe, and Japan, and has been tested in trials involving 500 humans, where it has had an outstanding safety record and reproducible immunogenicity.

Activity

• The Enemy of My Enemy is My Friend: Viral Version https://lnkd.in/dQuPm5U

• The Enemy of My Enemy is My Friend: Viral Version https://lnkd.in/dQuPm5U

• Liked by Harriet L. Robinson

Experience

• GeoVax Labs, Inc.

• 20 years

  • Director HIV Vaccines
    2016 - Present5 years
    USA

  • Chief Scientific Officer
    2010 - 20166 years
    Smryna, GA

  • Senior Vice President, Research and Development
    2008 - 20102 years
    Smyrna, GA

  • Scientific Advisor
    2001 - 20087 years

  • Co-Founder
    2001 - 2001less than a year

• Asa Griggs Candler Professor of Microbiology and Immunology
  Emory University
  1999 - 20089 years
  Atlanta, GA

• Yerkes National Primate Research Center, Emory University

• 11 years

  • Chief, Division of Microbiology and Immunology
    1997 - 200811 years
    Atlanta, GA

  • Professor, Department of Microbiology and Immunology
    1997 - 200811 years
    Atlanta, GA

• Professor, Department of Pathology
  University of Massachusetts Medical Center
  1988 - 19979 years
  Worcester, MA

• Worcester Foundation for Experimental Biology

• 10 years

  • Co-Director, Cancer Center
    1986 - 19871 year

  • Staff, then Senior, then Principal Science
    1977 - 198710 years

• Family Years at Home
  Home
  1967 - 197710 years

• National Science Foundation Fellow
  University of California, Berkeley; Laboratory of Dr. Harry Rubin
  1965 - 19672 years
  Berkeley, CA

• Candidate for a Doctoral Degree
  MIT; Dr. James E. Darnell, Thesis Advisor
  1963 - 19652 years
  Cambridge, MA

Education

• Massachusetts Institute of Technology
  Ph.D.
  1962 - 1965

• Massachusetts Institute of Technology
  M.S.
  1959 - 1961

• Swarthmore College
  B.A.
  1955 - 1959

• Girls’ Latin School
  -
  1951 - 1955

Publications

• A Single Dose of Modified Vaccinia Ankara expressing Ebola Virus Like Particles Protects Nonhuman Primates from Lethal Ebola Virus Challenge
  Sci Rep. 2018 Jan 16;8(1):864. doi: 10.1038/s41598-017-19041-y January 16, 2018
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
  J Virol. 2017 Nov 30;91(24). pii: e01077-17. doi: 10.1128/JVI.01077-17. Print 2017 Dec 15 November 30, 2017
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• A Zika Vaccine Targeting NS1 Protein Protects Immunocompetent Adult Mice in a Lethal Challenge Model
  Sci Rep. 2017 Nov 7;7(1):14769. doi: 10.1038/s41598-017-15039-8 November 7, 2017
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• HIV transmitted/founder vaccines elicit autologous tier 2 neutralizing antibodies for the CD4 binding site
  PLoS One 2017 Oct 11;12(10):e0177863. doi: 10.1371/journal.pone.0177863. eCollection 2017 October 11, 2017
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults
  PLoS One Jul 20;12(7):e0179597. doi: 10.1371/journal.pone.0179597. eCollection 2017 July 20, 2017

• A phase 1 trial of a clade B HIV vaccine in HIV-uninfected adults evaluated the safety and immunogenicity of a DNA prime co-expressing GM-CSF (Dg) followed by different numbers and intervals of modified vaccinia Ankara Boosts (M). Both vaccines produce virus-like particles presenting membrane-bound Env.

• Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• Local control of rectal challenges in DNA/MVA vaccinated macaques protected against a 1st series of SIV challenges
  Journal of Virology; 88(10): 5864-5869 Feb 2014
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles
  Journal of Infectious Diseases; 210:99-110 Jan 2014
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• Non-neutralizing antibodies in prevention of HIV infection
  Opinion on Biological Therapy; 13(2): 197-207 Feb 2013
  See publication

• Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
  Journal of Infectious Diseases; 203(5); 610-619 2011
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• HIV-1 DNA/MVA Vaccination Reduces the Per Exposure Probability of Infection during Repeated Mucosal SHIV Challenges
  Virology; 352:216-25 Aug 2006
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

• DNA/MVA vaccine for HIV type 1: effects of codon-optimization and the expression of aggregates or virus-like particles on the immunogenicity of the DNA prime.
  AIDS Res Hum Retroviruses; 20:1335-47 Dec 2004
  Other authors

  • 
    

  • 
    

  • 
    

  • 
    

  • 
    

• See publication

Honors & Awards

• Editorial Appointments
  -
  2015

• 2006 - current Journal of Infectious Diseases, Editorial Board

• 2006 - current Journal of Virology, Editorial Board
  2006 - 2011 Clinical and Vaccine Immunology, Editorial Board
  1993 – 2001 Virology, Section Editor
  1986 – 1993 Virology, Editorial Board
  1983 – 1992 Journal of Virology, Editorial Board

• Groundbreakers Award
  Atlanta Magazine, Atlanta, GA
  2012

• Distinguished Faculty Member
  Emory University Emeritus College, Atlanta, GA
  2011

• Georgia Bio Community Award
  Georgia Bio, Atlanta, GA
  2011

• Member-at-Large, Medical Sciences Section
  Fellow Association for the Advancement of Science
  2010

• Fellow, American Association for the Advancement of Science
  -
  2008

• Dean's Distinguished Faculty Lecturer and Award
  Emory University School of Medicine
  2007

• The Mary Lynn Morgan Annual Lectureship on Women in the Health Professions
  Center for Women at Emory University
  2006

• Member of Electorate Nominating Committee
  AAAS - American Association for the Advancement of Science
  2005

• Atlanta Business Chronicle Healthcare Hero
  Atlanta Business Chronicle, Atlanta, GA
  2003

• Albert E. Levy Scientific Research Award
  Emory University
  2002

• Fellow & Member, Board of Governors
  American Academy of Microbiology
  2002

• Most cited paper in Immunology
  Science
  2002

• November/December; Science 292:69:74

Organizations

• American Association of Immunologists
  -

• American Society of Microbiology
  -

• American Society of Virology
  -